10-Q: PTC Therapeutics Reports Strong Q3 with Novartis Boost

PTC Therapeutics achieved significant net income and revenue growth in Q3 2025, primarily driven by a $1.0 billion upfront payment from its Novartis collaboration, despite product revenue declines for Translarna and Emflaza.

Summary

• Net income attributable to common stockholders was $817.6 million for the nine months ended September 30, 2025, a substantial improvement from a net loss of $297.4 million in the same period of 2024.
• Total revenues for the nine months ended September 30, 2025, increased to $1,565.9 million from $593.6 million in 2024, largely due to a $1.0 billion collaboration and license revenue from Novartis.
• Net product revenue decreased by 10% to $402.7 million for the nine months ended September 30, 2025, compared to $446.2 million in 2024, primarily due to declines in Translarna and Emflaza sales.
• Sephience (sepiapterin) received FDA approval on July 28, 2025, and EC marketing authorization on June 19, 2025, for PKU treatment, generating $19.6 million in net sales in Q3 2025.
• The FDA issued a Complete Response Letter for vatiquinone for Friedreich's ataxia in August 2025, requiring an additional study for efficacy.
• Translarna's conditional marketing authorization in the European Economic Area was not renewed by the EC in March 2025, though individual EU countries may allow continued use.
• Emflaza's orphan drug exclusivity for patients aged five years and older expired in February 2024, leading to increased generic competition and reduced sales.
• Research and development expenses decreased by 21% to $322.1 million for the nine months ended September 30, 2025, partly due to a $65.0 million regulatory milestone paid in the prior year.
• Selling, general and administrative expenses increased by 16% to $250.3 million, reflecting continued investment in commercial activities.
• Cash provided by operating activities was $745.5 million for the nine months ended September 30, 2025, a significant turnaround from $77.7 million used in 2024.
• The accumulated deficit significantly improved from $(1,098.1) million at December 31, 2024, to $(155.8) million at September 30, 2025.
• The One Big Beautiful Bill Act (OBBBA) enacted on July 4, 2025, restored immediate deductibility of domestic R&D expenditures, contributing to an income tax benefit.

Sentiment

Score: 7

Explanation: The significant net income and revenue growth, driven by the Novartis collaboration, along with new product approvals (Sephience, Kebilidi), are strong positives. However, the regulatory setbacks for Translarna in Europe and vatiquinone in the US, coupled with the expiration of Emflaza's exclusivity, introduce notable challenges and risks, tempering the overall positive sentiment.

Positives

• Achieved significant net income of $817.6 million for the nine months ended September 30, 2025, a substantial improvement from a net loss in the prior year.
• Total revenues surged to $1,565.9 million, primarily driven by a $1.0 billion upfront payment from the Novartis collaboration for the votoplam HD program.
• Sephience received FDA approval in the U.S. and marketing authorization in the EEA for PKU treatment, generating initial net sales of $19.6 million in Q3 2025.
• Upstaza/Kebilidi net product sales increased to $36.3 million for the nine months ended September 30, 2025, following FDA approval in November 2024.
• Royalty revenue from Evrysdi sales increased by 13% to $164.8 million, indicating strong performance of the SMA program.
• Votoplam Phase 2 study met primary endpoints of blood HTT lowering and safety, with favorable clinical trends and Fast Track designation from the FDA.
• Cash provided by operating activities saw a major positive swing to $745.5 million, largely due to the Novartis upfront payment.
• The accumulated deficit was significantly reduced from $(1,098.1) million to $(155.8) million.
• The One Big Beautiful Bill Act (OBBBA) positively impacted income tax benefit by restoring immediate deductibility of domestic R&D expenditures.

Negatives

• Net product revenue decreased by 10% for the nine months ended September 30, 2025, primarily due to declines in Translarna and Emflaza sales.
• Translarna's conditional marketing authorization in the European Economic Area was not renewed by the EC, posing a substantial risk to future revenue from the region.
• Emflaza's orphan drug exclusivity for patients aged five years and older expired in February 2024, leading to increased generic competition and a decrease in sales.
• The FDA issued a Complete Response Letter for vatiquinone for Friedreich's ataxia, indicating a need for an additional adequate and well-controlled study to demonstrate efficacy.
• Translarna's NDA resubmission to the FDA has no action date, implying an uncertain and potentially prolonged review timeline.
• Selling, general and administrative expenses increased by 16% due to continued investment in commercial activities, which could impact profitability if product revenues do not grow sufficiently.

Risks

• The outcome of pricing, coverage, and reimbursement negotiations with third-party payors for products or product candidates may not be favorable.
• Ability to maintain marketing authorization for Translarna in Brazil, Russia, and other regions is uncertain following the EC's negative opinion.
• The EC's adoption of the CHMP's negative opinion for Translarna renewal could influence other regulatory bodies and significantly reduce revenue from the EEA.
• Study 041 and international drug registry data may not be sufficient to support a marketing approval for Translarna in the United States.
• Investigators may not agree with the company's interpretation of clinical trial results and totality of clinical data for Translarna.
• The FDA may not consider huntingtin protein lowering a surrogate endpoint for accelerated approval of votoplam without additional supportive data.
• Vatiquinone requires an additional adequate and well-controlled study to support NDA resubmission following the FDA's Complete Response Letter.
• The expiration of Emflaza's orphan drug exclusivity for patients five years and older is expected to have a significant negative impact on net product revenue.
• Ability to obtain additional and maintain existing reimbursed named patient and cohort early access programs for products on adequate terms, or at all, is a concern.
• Estimates regarding expenses, future revenues, and capital requirements may be inaccurate, potentially leading to a need for additional financing sooner than expected.
• The company's ability to realize anticipated benefits from acquisitions or strategic transactions, including obtaining marketing approval for acquired product candidates, is uncertain.
• The rate and degree of market acceptance and clinical utility of any products or product candidates may be lower than anticipated.
• The ability and willingness of patients and healthcare professionals to access products through alternative means if pricing and reimbursement negotiations are unfavorable is a risk.
• The timing of, and ability to obtain, additional marketing authorizations for products and product candidates is uncertain.
• The ability of products and product candidates to meet existing or future regulatory standards is not guaranteed.
• The ability to establish and maintain arrangements for the manufacture of products and product candidates sufficient for clinical trial and commercial launch requirements is critical.
• The company's ability to complete any post-marketing requirements imposed by regulatory agencies with respect to its products is ongoing.
• The ability to satisfy obligations under lease agreements and the 1.50% convertible senior notes due September 15, 2026, is a financial risk.
• The timing and conduct of ongoing, planned, and potential future clinical trials and studies for splicing and inflammation and ferroptosis programs, as well as studies for maintaining authorizations, label extensions, and additional indications, are subject to uncertainty.
• The impact of government laws and regulations, such as the EU's Pillar Two Directive, could materially adversely affect the company's business.
• The impact of litigation that has been or may be brought against the company, or that the company is pursuing against others, could be significant.
• The company's competitive position could be eroded by new entrants or superior therapies.

Future Outlook

The company expects to continue incurring significant expenses for commercialization, R&D, and clinical trials for its splicing and inflammation and ferroptosis programs. It aims to meet with the FDA in Q4 2025 to discuss Phase 3 clinical trial design and potential accelerated approval pathway for votoplam. Discussions with the FDA are also planned for Q4 2025 regarding the vatiquinone development program following the Complete Response Letter. The company believes current cash flows, cash equivalents, and marketable securities will be sufficient to fund operations for at least the next twelve months, but acknowledges that additional funding may be required.

Management Comments

• We are advancing a robust and diversified pipeline of transformative medicines as part of our mission to provide access to best-in-class treatments for patients with unmet medical needs.
• Our strategy is to leverage our scientific expertise and global commercial infrastructure to optimize value for our patients and other stakeholders.
• We continue to collaborate with Novartis on next steps for votoplam and aim to meet with FDA in the fourth quarter of 2025 to discuss Phase 3 clinical trial design and potential accelerated approval pathway.
• We plan to meet with the FDA in the fourth quarter to discuss the vatiquinone development program.
• We anticipate that we will continue to incur significant expenses in connection with our commercialization efforts in the United States, the EEA, Latin America and other territories.
• We believe that our cash flows from product sales, together with existing cash and cash equivalents, and marketable securities, will be sufficient to fund our operating expenses and capital expenditure requirements for at least the next twelve months.

Industry Context

The biopharmaceutical industry continues to see significant activity in rare disease treatments, with a focus on gene therapies and small molecule compounds. PTC Therapeutics' approvals for Sephience (PKU) and Kebilidi (AADC deficiency) align with this trend, addressing high unmet medical needs. The collaboration with Novartis for Huntington's disease highlights the industry's move towards strategic partnerships to de-risk and accelerate development for complex neurological disorders. However, the regulatory challenges faced by Translarna in Europe and vatiquinone in the US underscore the inherent risks and stringent requirements in drug development and commercialization, even for orphan drugs. The expiration of Emflaza's orphan drug exclusivity reflects the competitive pressures and lifecycle management challenges in the rare disease market.

Comparison to Industry Standards

• The $1.0 billion upfront payment from Novartis for the votoplam HD program is a substantial deal, comparable to high-value early-stage or mid-stage asset licensing agreements seen in the biopharmaceutical industry for promising neurological candidates, reflecting strong confidence in the asset's potential.
• The FDA's Complete Response Letter for vatiquinone for Friedreich's ataxia, requiring an additional study, is a common occurrence in drug development, particularly for rare diseases where clinical endpoints can be challenging. This is not unusual when compared to other companies facing similar regulatory hurdles for novel therapies.
• The decline in Translarna sales following the EC's negative opinion is a direct consequence of regulatory decisions, a risk factor common to all pharmaceutical companies operating in highly regulated markets like the EU. This mirrors challenges faced by other companies whose conditional approvals were not renewed.
• The expiration of Emflaza's orphan drug exclusivity and subsequent generic competition is a standard lifecycle event in the pharmaceutical industry, impacting revenue as expected for drugs losing patent protection or exclusivity.
• The increase in royalty revenue from Evrysdi (risdiplam) indicates strong market penetration and acceptance for this SMA treatment, performing well against competitors like Spinraza (Biogen) and Zolgensma (Novartis) in a competitive but growing market for SMA therapies.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently aware of any material legal proceedings against it.

Related Party Transactions

• The company has a royalty purchase agreement with Royalty Pharma Investments 2019 ICAV (Royalty Pharma) for Evrysdi royalties, with $1.9 billion in upfront cash consideration received to date and options for additional sales of retained royalty rights.
• The company entered into a License and Collaboration Agreement with Novartis Pharmaceuticals Corporation for its votoplam HD program, which included a $1.0 billion upfront payment and potential future milestones, profit sharing, and royalties.
• The company entered into a Rights Satisfaction Agreement with former Censa securityholders, paying $225.1 million upfront cash and agreeing to potential additional milestone payments up to $500.0 million based on Sephience net sales thresholds, in exchange for the cancellation of certain contingent payment rights.

Stakeholder Impact

• **Shareholders:** Significant net income and revenue growth, driven by the Novartis deal, could positively impact shareholder value. However, product revenue declines for Translarna and Emflaza, and regulatory setbacks for vatiquinone, introduce uncertainty.
• **Patients:** New approvals for Sephience (PKU) and Kebilidi (AADC deficiency) provide new treatment options for patients with rare disorders. Continued commercial use of Translarna in some EU countries, despite the EC's decision, may allow patients to maintain access.
• **Employees:** Increased selling, general and administrative expenses suggest continued investment in commercial infrastructure and personnel. Management trading arrangements indicate ongoing equity-based compensation.
• **Customers/Distributors:** Changes in product availability and pricing, particularly for Translarna in Europe and Emflaza due to generic competition, will impact distributors and healthcare providers.
• **Regulatory Bodies:** The company's ongoing interactions with the FDA and EMA regarding Translarna, votoplam, and vatiquinone highlight the continuous regulatory scrutiny and the need for robust clinical evidence.

Next Steps

• Meet with the FDA in Q4 2025 to discuss Phase 3 clinical trial design and potential accelerated approval pathway for votoplam.
• Meet with the FDA in Q4 2025 to discuss the vatiquinone development program following the Complete Response Letter.
• Await regulatory decisions for Sephience for PKU in Brazil and Japan, expected in Q4 2025.
• Continue efforts to maintain marketing authorization for Translarna in Brazil, Russia, and other regions.
• Continue to seek marketing authorization for Translarna for nmDMD in territories where it is not currently authorized.
• Monitor the impact of generic competition on Emflaza net product revenue following the expiration of orphan drug exclusivity.
• Manage the remaining $93.0 million aggregate offering price available under the At the Market Offering Sales Agreement.
• Evaluate potential exercise of remaining put options to sell retained Evrysdi Royalty rights to Royalty Pharma for additional payments.

Key Dates

Recommendation

While the significant net income and revenue boost from the Novartis collaboration is a strong positive, and new product approvals for Sephience and Kebilidi are encouraging, the company faces substantial headwinds. The loss of Translarna's EU authorization and Emflaza's orphan drug exclusivity, coupled with the FDA's Complete Response Letter for vatiquinone, introduce significant uncertainty and potential revenue erosion. The stock may see short-term positive reaction to the strong headline numbers, but long-term growth will depend on successful navigation of these regulatory and competitive challenges, and the development of its pipeline. A 'hold' recommendation is appropriate as investors should monitor the progress of votoplam's accelerated approval pathway and the company's strategy to mitigate the impact of the recent setbacks before making further investment decisions.

Keywords

Rare Disorders, Biopharmaceutical, PKU, Phenylketonuria, Sephience, Duchenne Muscular Dystrophy, DMD, Translarna, Emflaza, AADC Deficiency, Kebilidi, Upstaza, Huntington's Disease, Votoplam, Friedreich's Ataxia, Vatiquinone, SMA, Evrysdi, Novartis Collaboration, FDA Approval, EC Authorization, Orphan Drug Exclusivity, Clinical Trials, Gene Therapy, Splicing Platform, Inflammation and Ferroptosis